J Louise I Burggraaf-van Delft, Nienke van Rein, Remy H H Bemelmans, Jan-Willem K van den Berg, Coty Y Bruggeman, Marissa Cloos-van Balen, Michiel Coppens, Matthijs Eefting, Yvonne Ende-Verhaar, Nick van Es, Coen van Guldener, Wouter K de Jong, Fleur Kleijwegt, Ted Koster, Cees Kroon, Saskia Kuipers, Jenneke Leentjens, Dieuwke Luijten, Albert T A Mairuhu, Karina Meijer, Marcel A van de Ree, Rick Roos, Ilse Schrover, Janneke Swart-Heikens, Annette W G van der Velden, Elske M van den Akker-van Marle, Saskia le Cessie, Geert-Jan Geersing, Saskia Middeldorp, Menno V Huisman, Frederikus A Klok, Suzanne C Cannegieter
INTRODUCTION: Patients with a first venous thromboembolism (VTE) are at risk of recurrence. Recurrent VTE (rVTE) can be prevented by extended anticoagulant therapy, but this comes at the cost of an increased risk of bleeding. It is still uncertain whether patients with an intermediate recurrence risk or with a high recurrence and high bleeding risk will benefit from extended anticoagulant treatment, and whether a strategy where anticoagulant duration is tailored on the predicted risks of rVTE and bleeding can improve outcomes...
March 23, 2024: BMJ Open